Abstract
During the last few decades, we have witnessed major improvements in the therapy of pulmonary arterial hypertension (PAH). PAH is characterized by abnormal remodeling of the pulmonary artery (PA) and increased PA pressures, resulting in a high premature mortality. Intravenous epoprostenol was the first effective approach toward improving the symptoms and survival of PAH patients. New prostanoids have also exhibited substantial clinical benefits; however, their long-term effects are under investigation. Endothelin-receptor antagonists and sildenafil have increased the lineup of therapeutic options against PAH. Combination therapy using these drugs is promising and is currently undergoing scrutiny in large clinical trials. An extensive analysis of the molecular mechanisms of PAH will produce novel targeted therapies. Most of the promising molecules target the inflammatory and proliferative processes underlying pathological PA remodeling. Interestingly, drugs used for other diseases, such as statins, Rho-kinase inhibitors, imatinib mesylate, may control the pathological vascular remodeling of PAH. Gene and cell therapy using vectors expressing prostacyclin synthase, endothelial nitric oxide synthase, or vascular endothelial growth factor are also promising strategies. However, the efficacy and safety of these approaches should be further tested in clinical trials. Genetic studies revealed some crucial genetic dispositions of familial PAH, although their pathobiological roles have not yet been fully clarified. Collaboration for integrated research will address these issues and generate greater clinical benefits for PAH patients.
Keywords: Pulmonary arterial hypertension, treatment, prostacyclin, endothelin, sildenafil, gene therapy, inflammation, proliferation
Current Medicinal Chemistry
Title: Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Volume: 14 Issue: 6
Author(s): Takayuki Ito, Keiya Ozawa and Kazuyuki Shimada
Affiliation:
Keywords: Pulmonary arterial hypertension, treatment, prostacyclin, endothelin, sildenafil, gene therapy, inflammation, proliferation
Abstract: During the last few decades, we have witnessed major improvements in the therapy of pulmonary arterial hypertension (PAH). PAH is characterized by abnormal remodeling of the pulmonary artery (PA) and increased PA pressures, resulting in a high premature mortality. Intravenous epoprostenol was the first effective approach toward improving the symptoms and survival of PAH patients. New prostanoids have also exhibited substantial clinical benefits; however, their long-term effects are under investigation. Endothelin-receptor antagonists and sildenafil have increased the lineup of therapeutic options against PAH. Combination therapy using these drugs is promising and is currently undergoing scrutiny in large clinical trials. An extensive analysis of the molecular mechanisms of PAH will produce novel targeted therapies. Most of the promising molecules target the inflammatory and proliferative processes underlying pathological PA remodeling. Interestingly, drugs used for other diseases, such as statins, Rho-kinase inhibitors, imatinib mesylate, may control the pathological vascular remodeling of PAH. Gene and cell therapy using vectors expressing prostacyclin synthase, endothelial nitric oxide synthase, or vascular endothelial growth factor are also promising strategies. However, the efficacy and safety of these approaches should be further tested in clinical trials. Genetic studies revealed some crucial genetic dispositions of familial PAH, although their pathobiological roles have not yet been fully clarified. Collaboration for integrated research will address these issues and generate greater clinical benefits for PAH patients.
Export Options
About this article
Cite this article as:
Ito Takayuki, Ozawa Keiya and Shimada Kazuyuki, Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension, Current Medicinal Chemistry 2007; 14 (6) . https://dx.doi.org/10.2174/092986707780059562
DOI https://dx.doi.org/10.2174/092986707780059562 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endothelin-1 and Human Platelets
Current Vascular Pharmacology The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque
Current Pharmaceutical Design Editorial: (Persistent Elevation of Blood Pressure in Children and Adolescents is Associated with Arterial Hypertension and Premature Atherosclerosis in Adults. Is it Possible to Reverse this?)
Current Vascular Pharmacology Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Lipids, Statins and Heart Failure: An Update
Current Pharmaceutical Design JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry In Vivo Electroporation of Gene Sequences for Therapeutic and Vaccination Applications
Recent Patents on DNA & Gene Sequences The Role of Cannabinoid Receptors in Renal Diseases
Current Medicinal Chemistry Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old
Current Alzheimer Research Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)
Current Medicinal Chemistry Gallic Acid Attenuates Oleic Acid-induced Proliferation of Vascular Smooth Muscle Cell Through Regulation of AMPK-eNOS-FAS Signaling
Current Medicinal Chemistry Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials
Current Pharmaceutical Design Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology